Azacitidine is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 138 clinical trials, of which 92 were completed, 41 are ongoing, and 5 are planned.
Azacitidine is DNA (cytosine-5-)-methyltransferase 1(DNMT1) inhibitor. Inhibition of DNMT1 leads to hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways. Non-proliferating cells are relatively insensitive to azacitidine. Incorporation of azacitidine into DNA results in the inactivation of DNA methyltransferases, leading to hypomethylation of DNA. DNA hypomethylation of aberrantly methylated genes involved in normal cell cycle regulation, differentiation and death pathways may result in gene re-expression and restoration of cancer-suppressing functions to cancer cells.
The revenue for Azacitidine is expected to reach a total of $333m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Azacitidine NPV Report.
Azacitidine (Vidaza, Azafuridine, Celazadine) is a pyrimidine analog acts as an anti-anemic, anti-neoplastic agent. It is formulated as lyophilized powder for suspension and solution for intravenous, and subcutaneous route of administration. It is indicated for the treatment of myelodysplastic syndromes (MDS). It is indicated used for all 5 FAB (French-American-British) subtypes of myelodysplastic syndromes (MDS) which include refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T) and chronic myelomonocytic leukemia (CMMoL). Vidaza is also indicated for the treatment of adult patients aged 65 years or older with acute myeloid leukemia (AML) who are not eligible for hematopoietic stem cell transplantation (HSCT) and indicated for the treatment of adult patients who are not eligible for hematopoietic stem cell transplantation (HSCT) with intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder and acute myeloid leukemia (AML) with 20-30% blasts and multi-lineage dysplasia. Vidaza is indicated for the treatment of pediatric patients aged one month and older with newly diagnosed JMML.
Injectable azacitidine is under development for newly diagnosed advanced myelodysplastic syndrome, myeloproliferative neoplasm, osteosarcoma, multiple myeloma and relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, adult T-cell leukemia/lymphoma, extranodal NK-/T-cell lymphoma, nasal type, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like t-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, primary cutaneous T-cell lymphoma, primary cutaneous CD8+ T-cell lymphoma, transformed mycosis fungoides, primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, ALK- and ALK+ anaplastic large-cell lymphoma.
It was also under development for treatment of as a second line therapy for transitional cell cancer (urothelial cell cancer), epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer pancreatic cancer, nasopharyngeal carcinoma, cervical carcinoma, anal carcinoma and merkel cell carcinoma (MCC).
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.
Quick View – Azacitidine
|Highest Development Stage|